Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion

NCT02576431 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02576431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
September 29, 2025
Enrollment
215 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors harboring ntrk fusion